Gotham Therapeutics Corporation

https://www.gothamtx.com

Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins. By changing the activity of proteins that modify messenger RNA, we aim to develop new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. We are applying a 360-degree approach to small molecule drug design to build a pipeline based on the promise of this rapidly emerging biopharmaceutical field. *

	Start	2018-10-10 existent
	Group	Gotham Therapeutics (Group)
	Industry	oxycodone (INN)
	Industry 2	drug discovery
	Person	Babiss, Lee E. (Gotham Therapeutics 201810 CEO before Roche+ PPD + Glaxo Wellcome)
	Person 2	Zech, Birgit (Anavo Therapeutics 202104 CEO before Gotham Therapeutics + X-Rx + MAB Discovery + Pieris + Axxima)

	Region	New York, NY
	Country	United States (USA)
	Street	430 East 29th Street Alexandria Center for Life Science, Suite 1435
	City	10016 New York, NY
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Gotham Therapeutics Corporation. (10/10/18). "Press Release: Gotham Therapeutics Launches with $54 Million Series A". New York, NY.

		Record changed: 2023-07-10